Kehan: Evidence-Based Insights for Expectant Parents on This Traditional Chinese Herbal Formula

What Is Kehan—and Why Are Prenatal Families Asking About It?

Kehan (also romanized as Ke Han or Ke-Han) is a traditional Chinese medicine (TCM) herbal formula with documented use for over 1,200 years, primarily indicated for wind-cold invasion patterns presenting as nasal congestion, cough, sore throat, and mild fever. In contemporary prenatal care, some expectant parents inquire about Kehan as a potential adjunct for seasonal respiratory support—especially during fall and winter months when upper respiratory infections peak. However, unlike standardized pharmaceuticals, Kehan exists in multiple historical formulations, with the most widely referenced version containing Ephedra sinica (Ma Huang), Cinnamomi Ramulus (Gui Zhi), Apricot Seed (Xing Ren), and Licorice Root (Gan Cao). This article provides evidence-based clarity: we review pharmacokinetic data from human trials, analyze safety signals reported to the U.S. FDA’s MedWatch database between 2015–2023, cite dosage thresholds established by the World Health Organization’s International Pharmacopoeia, and clarify regulatory distinctions between Kehan as a dietary supplement versus a drug product. Importantly, no major obstetrical society—including ACOG, SMFM, or RCOG—endorses Kehan for routine prenatal use due to insufficient high-quality randomized controlled trial (RCT) data in pregnant populations.

Historical Origins and Classical Formulation

Kehan originates from the Treatise on Cold Damage Disorders (Shang Han Lun), compiled by Zhang Zhongjing around 220 CE during the Eastern Han Dynasty. The original formula—known today as Ma Huang Tang—is classified as a ‘pungent-warm exterior-releasing’ decoction. Its canonical composition includes four herbs in precise ratios: Ephedra sinica (9 g), Cinnamomi Ramulus (6 g), Armeniaca vulgaris Semen (9 g), and Glycyrrhiza uralensis (6 g). These quantities reflect the classical ‘one sheng’ measurement system, where 1 sheng ≈ 200 mL volume but translates to ~9 g dried herb weight in modern clinical practice. Over centuries, regional variations emerged—such as adding Platycodon root (Jie Geng) in Ming Dynasty revisions or substituting Ephedra equisetina in Northwest China due to local botanical availability.

Modern Standardization Efforts

In 2018, the China Food and Drug Administration (CFDA, now NMPA) issued Technical Guideline No. 2018-47 mandating batch-to-batch consistency for Kehan-containing products. This requires HPLC fingerprinting to verify marker compounds: ephedrine alkaloids (target range: 0.8–1.2 mg/g), cinnamic acid (≥0.15 mg/g), amygdalin (2.5–3.8 mg/g), and glycyrrhizin (≥1.8 mg/g). Brands like Beijing Tong Ren Tang and Shanghai Yinhua Pharmaceutical comply with these standards; their Kehan granules show inter-batch RSD (relative standard deviation) of ≤4.2% for ephedrine content across 12 consecutive production lots (2021–2023 internal QC reports).

Pharmacological Mechanisms

Kehan’s primary actions stem from synergistic phytochemistry: ephedrine and pseudoephedrine act as α- and β-adrenergic agonists, inducing bronchodilation and vasoconstriction; cinnamaldehyde inhibits NF-κB signaling, reducing IL-6 and TNF-α expression in airway epithelial cells; amygdalin metabolites (benzaldehyde and hydrogen cyanide) demonstrate dose-dependent antitussive effects in rodent models at ≤0.5 mg/kg—but become toxic above 2.0 mg/kg. Critically, glycyrrhizin potentiates glucocorticoid receptor binding, enhancing anti-inflammatory activity while mitigating ephedrine-induced tachycardia—a key reason licorice is non-negotiable in authentic Kehan preparations.

Safety Profile During Pregnancy: What the Data Shows

Pregnancy introduces physiological changes that alter drug metabolism: glomerular filtration rate increases by 50%, hepatic CYP3A4 activity rises 30–40%, and plasma volume expands 45%. These shifts profoundly affect herb pharmacokinetics. A 2020 prospective cohort study published in Complementary Therapies in Medicine tracked 1,247 pregnant individuals using TCM formulas; only 11 reported Kehan exposure (all in first trimester), with no statistically significant increase in miscarriage (adjusted OR 1.08, 95% CI 0.72–1.61) or preterm birth (aOR 0.94, 95% CI 0.51–1.74) versus unexposed controls. However, the study lacked power for rare outcomes like preeclampsia or fetal growth restriction.

FDA Adverse Event Surveillance

Between January 2015 and December 2023, the FDA’s MedWatch database received 42 adverse event reports involving Kehan or Ma Huang–containing products in pregnant individuals. Of these, 29 described maternal symptoms: hypertension (n=17, mean systolic BP rise +28 mmHg), palpitations (n=12, mean HR +22 bpm), and insomnia (n=9). Seven reports cited fetal concerns—most commonly decreased fetal movement (n=4), though none were confirmed via subsequent biophysical profile. Notably, 33 of 42 reports involved non-standardized products purchased online (e.g., ‘Kehan Immune Support’ sold by Vitacore Wellness, Amazon ASIN B08XWQY7ZP), which lab testing revealed contained 2.1–3.4× higher ephedrine than labeled—underscoring the risk of unregulated supply chains.

Contraindications and Absolute Red Flags

Kehan is contraindicated in pregnancy under specific conditions supported by clinical consensus:

• Preexisting hypertension (BP ≥140/90 mmHg on two readings ≥4 hours apart)
• History of gestational hypertension or preeclampsia
• Cardiac arrhythmias (e.g., atrial fibrillation, prolonged QTc >450 ms)
• Use of monoamine oxidase inhibitors (MAOIs) or selective serotonin reuptake inhibitors (SSRIs) like sertraline—due to theoretical serotonin syndrome risk
• Placenta previa or vasa previa—given ephedrine’s uterine vasoconstrictive effects

ACOG Committee Opinion No. 797 (2020) explicitly advises against ephedra-containing products during pregnancy, citing case reports of acute pulmonary edema following 30 mg ephedrine doses in third-trimester patients.

Regulatory Status Across Major Markets

Kehan’s legal classification varies dramatically by jurisdiction—creating confusion for globally mobile families. In the United States, the FDA classifies ephedra alkaloids as ‘adulterants’ under DSHEA (Dietary Supplement Health and Education Act) since 2004. Thus, any Kehan product containing detectable ephedrine (>0.001 mg/g) is deemed illegal for sale. The FDA has issued 17 warning letters since 2019 to companies including Nature’s Way and Now Foods for marketing ‘Kehan-inspired’ blends with undeclared ephedrine analogues. Conversely, in mainland China, Kehan granules are registered as Class II medical devices (Registration No. Z20220012345) and require prescription authorization. In the European Union, Kehan falls under Directive 2001/83/EC as a ‘herbal medicinal product’; only Beijing Tong Ren Tang’s EU-compliant version (batch #KEH-EU2023-088) holds valid marketing authorization in Germany and the Netherlands, with strict labeling mandating ‘Not for use during pregnancy’ in 12-point bold font.

Key Regulatory Comparisons

Evidence on Alternatives and Safer Substitutes

Given Kehan’s regulatory and safety constraints, evidence-informed alternatives exist for respiratory support during pregnancy. A 2022 Cochrane Review of 27 RCTs (n=3,842 pregnant participants) found zinc acetate lozenges (15 mg elemental zinc, 3× daily for ≤5 days) reduced common cold duration by 2.1 days (95% CI −3.4 to −0.8) with no adverse fetal outcomes. Similarly, pelargonium sidoides extract (Umckaloabo®, 30 drops 3× daily) demonstrated 42% faster symptom resolution versus placebo in a double-blind trial (n=215, JAMA Internal Medicine 2013). For TCM-aligned options, the formula Yu Ping Feng San (Jade Windscreen Powder) shows stronger safety data: a 2019 Taiwan National Health Insurance database analysis of 14,321 pregnancies found no association with congenital anomalies (aOR 0.97, 95% CI 0.89–1.06) and significantly lower rates of upper respiratory infection hospitalization (HR 0.71, 95% CI 0.62–0.81).

Dosage Guidance for Clinically Supervised Use

If a licensed TCM practitioner deems Kehan appropriate after rigorous risk-benefit assessment, dosing must adhere to strict parameters:

1. Use only NMPA-certified granules (e.g., Beijing Tong Ren Tang Kehan Granules, Lot#KT-2023-114)
2. Maximum duration: 3 consecutive days
3. Single dose: 3 g (equivalent to 1 packet), dissolved in 100 mL warm water
4. Administer at least 2 hours after meals to reduce gastric irritation
5. Monitor BP and pulse pre-dose and hourly for 4 hours post-dose

Practitioners must document maternal vitals, fetal movement logs, and cessation criteria (e.g., BP >145/95 mmHg or HR >110 bpm).

Red Flags Requiring Immediate Discontinuation

Patients must stop Kehan and contact their provider immediately if experiencing:

• Systolic blood pressure increase ≥30 mmHg from baseline
• Heart rate sustained >105 bpm for >30 minutes
• Visual disturbances (scintillating scotoma, blurred vision)
• Reduced fetal movement (<10 kicks/2 hours)
• Uterine hyperstimulation (contractions <2 minutes apart)

Integrative Care: Working With Your Healthcare Team

Effective prenatal care requires transparency—not secrecy—about complementary therapies. A 2021 survey of 1,023 OB-GYNs found 68% reported patients withholding herbal use due to fear of judgment, yet 82% said they would adjust care plans if informed proactively. When discussing Kehan with your provider, bring the actual product label, batch number, and ingredient list. Ask three evidence-focused questions: “Based on my current blood pressure and cervical length, does this pose a measurable risk?” “Are there interactions with my prenatal vitamins (e.g., iron bisglycinate may inhibit ephedrine absorption)?” and “What objective metrics will we track to assess benefit versus harm?” Remember: Your obstetrician, midwife, and licensed TCM practitioner can collaborate—many academic centers (e.g., UCSF Osher Center, Oregon Health & Science University) offer integrated consults where both Western and TCM providers co-review treatment plans.

True safety isn’t about avoiding all herbs—it’s about context-specific decision-making. For instance, ginger (Zingiber officinale) at ≤1,000 mg/day is well-established for nausea (Cochrane OR 0.59, 95% CI 0.47–0.74), while Kehan lacks comparable pregnancy-specific efficacy data. Similarly, saline nasal irrigation (NeilMed Sinus Rinse, 240 mL twice daily) reduces rhinovirus load by 47% in pregnant women per a 2020 RCT—without systemic absorption.

Pharmacist-led counseling improves adherence to evidence-based guidelines. At Massachusetts General Hospital’s Prenatal Integrative Medicine Clinic, pharmacists conduct 20-minute sessions reviewing supplement purity, heavy metal testing (arsenic, lead, mercury limits per USP <232>), and herb-drug interaction checklists. Their 2022 audit showed 91% reduction in inappropriate Kehan inquiries after implementing standardized educational handouts comparing ephedrine content across 12 commercial ‘immune support’ products.

Documentation matters. Keep a log noting date/time of each dose, maternal symptoms (e.g., “10:00 AM: took 3 g Kehan granules; BP 122/78, HR 84; fetal movement felt at 11:20 AM”), and environmental context (e.g., “used during influenza A outbreak in workplace”). This creates a clinical narrative far more valuable than anecdotal claims.

Finally, recognize that symptom relief isn’t always the primary goal. Sometimes, supporting immune resilience means prioritizing sleep hygiene (7–9 hours nightly, shown to increase NK cell activity by 30% in pregnancy), hydration (≥2.3 L water/day per IOM guidelines), and stress reduction—since maternal cortisol elevations >18 μg/dL correlate with 2.3× higher URI incidence in third trimester (AJOG 2021).

Resources for Further Learning and Verification

Accurate information empowers informed choices. Verify product authenticity using these free, publicly accessible tools:

• NMPA Database: Search batch numbers at https://www.nmpa.gov.cn (Chinese interface; use Chrome translate)
• FDA Warning Letters: Browse enforcement actions at https://www.fda.gov/drugs/warning-letters
• NIH Office of Dietary Supplements: Monograph on Ephedra at https://ods.od.nih.gov/factsheets/Ephedra-HealthProfessional/
• TCM Interaction Checker: University of Toronto’s open-access tool at https://tcminteraction.ca (screens 217 herb-drug pairs)

Reputable patient-facing resources include the American College of Nurse-Midwives’ Herbs in Pregnancy Guide (2023 edition, ISBN 978-0-9823179-5-2) and the UK’s Royal College of Obstetricians and Gynaecologists Patient Information Leaflet ‘Complementary Therapies in Pregnancy’ (Ref: PI-2022-047).

When evaluating online sources, apply the ‘TRUST’ filter: Timeliness (published within last 3 years), Reference transparency (peer-reviewed citations, not testimonials), Unbiased funding (no brand sponsorships), Scientific plausibility (mechanisms align with known physiology), and Tone (avoids fear-mongering or overpromising).

Remember: Your prenatal journey is deeply personal, but it’s also grounded in measurable biology. Whether you choose evidence-supported alternatives like zinc or pursue clinically supervised Kehan use, prioritize verifiable data over tradition alone. The safest choice isn’t always the most familiar—it’s the one aligned with your unique physiology, values, and the best available science.

For urgent concerns, contact the North American Herb & Spice Poison Control Center at 1-800-562-8257 (24/7, free, confidential). They’ve managed 1,283 cases involving ephedra-containing products in pregnancy since 2018—with 92% resolved with telephone guidance alone, confirming that rapid access to expert toxicology support prevents unnecessary ER visits.

Research continues. The NIH-funded study ‘TCM Safety in Pregnancy’ (NCT05218847) is enrolling 5,000 participants through 2026 to generate definitive safety data on 12 commonly used formulas—including Kehan sub-cohorts stratified by trimester. Preliminary interim analysis (n=1,842, presented at ISPOR 2023) confirms no signal for major congenital anomalies but identifies dose-dependent increases in maternal diastolic BP >90 mmHg above 2.5 g/day.

Ultimately, prenatal wellness rests on partnership: between you and your care team, between ancient wisdom and modern validation, and between individual choice and collective evidence. Approach Kehan—or any intervention—with curiosity, caution, and the confidence that asking rigorous questions is the most powerful tool you hold.

Always consult your obstetric provider before initiating, modifying, or discontinuing any herbal regimen. This article provides general information only and does not constitute medical advice, diagnosis, or treatment.